HUTCHMED (HCM) Stock Price, News & Analysis

Company Overview

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Key Stats

• Today's Range: $16.33 to $16.57
• 50-Day Range: $14.84 to $19.21
• 52-Week Range: $11.51 to $21.50
• Volume: 17,603 shs
• Average Volume: 82,481 shs
• Market Capitalization: $2.87 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.00
• Consensus Rating: Buy

HUTCHMED Stock Analysis - MarketRank™

HUTCHMED scored higher than 53% of companies evaluated by MarketBeat, and ranked 1091st out of 1,876 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

HUTCHMED has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

HUTCHMED has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 812.50%

Earnings Growth

Earnings for HUTCHMED are expected to grow by 812.50% in the coming year, from $0.16 to $1.46 per share.

Price to Book Value per Share Ratio

HUTCHMED has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.23% of the float of HUTCHMED has been sold short.

Short Interest Ratio / Days to Cover

HUTCHMED has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in HUTCHMED has recently increased by 10.13%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HUTCHMED does not currently pay a dividend.

Dividend Growth

HUTCHMED does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.23% of the float of HUTCHMED has been sold short.

Short Interest Ratio / Days to Cover

HUTCHMED has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in HUTCHMED has recently increased by 10.13%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.16

News Sentiment

HUTCHMED has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for HUTCHMED this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for HCM on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added HUTCHMED to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HUTCHMED insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.60% of the stock of HUTCHMED is held by insiders.

Percentage Held by Institutions

Only 8.82% of the stock of HUTCHMED is held by institutions.

HCM Stock Analysis - Frequently Asked Questions

How have HCM shares performed this year?

HUTCHMED's stock was trading at $14.41 at the start of the year. Since then, HCM stock has increased by 14.0% and is now trading at $16.43.

When did HUTCHMED IPO?

HUTCHMED (HCM) raised $100 million in an initial public offering (IPO) on Thursday, March 17th 2016. The company issued 6,100,000 shares at $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities served as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

Who are HUTCHMED's major shareholders?

Top institutional investors of HUTCHMED include Schroder Investment Management Group (1.48%), Allianz Asset Management GmbH (0.53%), M&G PLC (0.15%) and Jane Street Group LLC (0.10%).

How do I buy shares of HUTCHMED?

Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

• Today: 8/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HCM
• CIK: 1648257
• Web: www.chi-med.com
• Phone: 852-2121-3888
• Fax: 852-2128-1778
• Employees: 1,811
• Year Founded: 2000

Price Target and Rating

• Average Price Target for HUTCHMED: $28.00
• High Price Target: $28.00
• Low Price Target: $28.00
• Potential Upside/Downside: +70.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 4.65
• Quick Ratio: 4.51

Sales & Book Value

• Annual Sales: $630.20 million
• Price / Sales: 4.55
• Cash Flow: $0.29 per share
• Price / Cash Flow: 57.27
• Book Value: $4.43 per share
• Price / Book: 3.71

Miscellaneous

• Outstanding Shares: 174,420,000
• Free Float: 168,143,000
• Market Cap: $2.87 billion
• Optionable: Not Optionable
• Beta: 0.55